Join Growin Stock Community!

Nuvalent, inc.NUVL.US Overview

US StockHealthcare
(No presentation for NUVL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NUVL AI Insights

NUVL Overall Performance

NUVL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NUVL Recent Performance

-1.75%

Nuvalent, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

NUVL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NUVL Key Information

NUVL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NUVL Profile

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Price of NUVL

NUVL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NUVL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
9.36
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
9.36
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NUVL's latest earnings report released?

    The most recent financial report for Nuvalent, inc. (NUVL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NUVL's short-term business performance and financial health. For the latest updates on NUVL's earnings releases, visit this page regularly.

  • How much cash does NUVL have?

    At the end of the period, Nuvalent, inc. (NUVL) held Total Cash and Cash Equivalents of 261.75M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NUVL's EPS continuing to grow?

    According to the past four quarterly reports, Nuvalent, inc. (NUVL)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NUVL?

    Nuvalent, inc. (NUVL)'s Free Cash Flow (FCF) for the period is -73.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.27% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NUVL?

    The latest valuation data shows Nuvalent, inc. (NUVL) has a Price-To-Earnings (PE) ratio of -19.21 and a Price/Earnings-To-Growth (PEG) ratio of 2.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.